Currently, amyloid‐Positron Emission Tomography (PET), tau‐PET, and cerebrospinal fluid (CSF) are the gold standard for detecting amyloid and tau pathology in clinical trials.1, 2. The gene discussed is MAPT; the disease is amyloidosis.